

Elliot Staffin
Office of International Corporate Finance
U.S. Securities and Exchange Commissions,
Station Place Headquarters,
100 F. St. N.E.,
Washington, D.C. 20549
USA



PROCESSED
DEC 05 2005
THOMSON
FINANCIAL

SUPPL

RECEIVED
2005 DEC -1 P 2:54
OFFICE OF INTERNATIONAL
CORPORATE FINANCE

11/18/2005

Re.: SEC File Number, 82-5116


This information is furnished pursuant to Rule 12g3-2(b).

Kindly receive press release No. 39 of November sent to the Copenhagen Stock Exchange.

Yours sincerely
Novozymes A/S



Ella Begtrup
Investor Relations
+45 44 42 23 79



Novozymes A/S

Trading by insiders in Novozymes A/S B shares - statement no. 27, 2005

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B:

Name	Relation/ category of close relation	Trading date	Character of the transaction	No. of shares traded (buy / sell)	Market value of shares traded
Per Falholt	EVP and SCO	9/11-2005	Shares	- 3,000	976,500

Contact persons

Press and media:

Eva Veileborg Hald

Tel. (direct): +45 4442 3338

Annegrethe Jakobsen

Tel. (direct): +45 4442 3050

Investor Relations:

Lene Aaboe

Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl

Tel. (direct): +45 4443 3304

Tobias Cornelius Bjorklund

Tel. (direct): +45 4442 8682

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 4,000 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.